name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
c.A-3G	c.A-3G				28271	N	intergenic		24	24	24						0	G=24	24	G	A						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
c.C-25T	c.C-25T				241	orf1ab	5' UTR		24	24	24						0	T=24	24	T	C						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
c.C29769T	c.C*4385T				29769	intergenic	3' UTR		17	24	24						0	T=17	17	T	C						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
c.G29747A	c.G*4363A				29747	intergenic	Stem-loop,3' UTR		24	24	24						21	A=3	3	A	G						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.3676del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', 'F3677del'	11287	orf1ab	ORF1ab		48	48	24			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=48	48	G	GTCTGGTTTT						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.A208_R209delinsG	c.623_625delCTA	p.A208_R209delinsG			28895	N	N		24	24	24						0	G=24	24	G	GCTA						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.A3209V	c.C9626T	p.A3209V			9891	orf1ab	ORF1ab	MISSENSE	24	24	24			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=24	24	T	C						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.A575A	c.T1725C	p.A575A			23287	S	S	SILENT	24	24	24						0	C=24	24	C	T						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'Y144del'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'Y144del'	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'P681H'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'P681H'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'T95I'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'Y144del'	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	24	24	24						0	G=24	24	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.D6584D	c.C19752T	p.D6584D			20016	orf1ab	ORF1ab	SILENT	24	24	24			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	19	T=5	5	T	C						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.D796H	c.G2386C	p.D796H			23948	S	S	MISSENSE	24	24	24						0	C=24	24	C	G	convalescent plasma escape	Kemp et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.12.05.20241927v1		Fatal COVID-19 complications in immunocomprimised patient after immune escape from convalescent plasma	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E106X	c.G316T	p.E106X			28209	ORF8	ORF8	NONSENSE	24	24	24						0	T=24	24	T	G						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E1196V	c.A3587T	p.E1196V			3852	orf1ab	ORF1ab	MISSENSE	24	24	24			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	2	T=22	22	T	A						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.06 fold	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	antibody epitope effects	Li et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1		Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	antibody epitope effects	Liu et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1		Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Andreano et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.12.28.424451		This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Schmidt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1		"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	monoclonal antibody serial passage escape	Barnes et al. (2020)	https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin		The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	monoclonal antibody serial passage escape	Baum et al. (2020)	http://dx.doi.org/10.1126/science.abd0831		Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	trafficking	Ferriera et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	vaccine neutralization efficacy	Ferreira et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1		E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	vaccine neutralization efficacy	Jangra et al. (2021)	https://doi.org/10.1016/S2666-5247(21		Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	vaccine neutralization efficacy	Solfrosi et al. (2021)	https://doi.org/10.1084/jem.20202756		Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	24	24	24						0	A=24	24	A	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.E863E	c.A2589G	p.E863E			2854	orf1ab	ORF1ab	SILENT	24	24	24			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	21	G=3	3	G	A						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.F3677del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', '3676del'	11287	orf1ab	ORF1ab		24	24	24			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=24	24	G	GTCTGGTTTT						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	24	24	24			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=24	24	T	C						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.I1232I	c.C3696T	p.I1232I			3961	orf1ab	ORF1ab	SILENT	24	24	24			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=24	24	T	C						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.I2490I	c.C7470T	p.I2490I			7735	orf1ab	ORF1ab	SILENT	24	24	24			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	19	T=5	5	T	C						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.I82T	c.T245C	p.I82T			26767	M	M	MISSENSE	24	24	24						0	C=24	24	C	T	homoplasy	Shen et al. (2021)	https://doi.org/10.1080/22221751.2021.1922097		This mutation presents mainly within the B.1 (44.0%) and B.1.525 (38.1%) lineages.  Currently, 99.7% of the B.1.525 lineage isolates carry the M:I82T mutation. While this mutation is scattered across multiple  phylogenetic clades, most cases cluster in two recent clades, suggesting a likely selective advantage in certain haplotype backgrounds.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.K2511N	c.G7533T	p.K2511N			7798	orf1ab	ORF1ab	MISSENSE	24	24	24			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=24	24	T	G						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.L3919F	c.C11755T	p.L3919F			12020	orf1ab	ORF1ab	MISSENSE	48	48	24			nsp7	produced by both pp1a and pp1ab	YP_009725303.1	42	T=6	6	T	C						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.M1fs	c.-7_8delAACGAACATGAAATT	p.M1fs			27886	ORF8	intergenic		24	24	24			(ORF8|Gene_27893_28258|1|1.00)			0	A=24	24	A	AAACGAACATGAAATT						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.N3205N	c.T9615C	p.N3205N			9880	orf1ab	ORF1ab	SILENT	24	24	24			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	21	C=3	3	C	T						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.N3291N	c.C9873T	p.N3291N			10138	orf1ab	ORF1ab	SILENT	24	24	24			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	21	T=3	3	T	C						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.N4889N	c.C14667T	p.N4889N			14931	orf1ab	ORF1ab	SILENT	24	24	24			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	21	T=3	3	T	C						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.P1921P	c.A5763G	p.P1921P			6028	orf1ab	ORF1ab	SILENT	24	24	24			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	21	G=3	3	G	A						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	24	24	24			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	T=24	24	T	C						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	24	24	24						0	A=24	24	A	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.23x decrease in binding (KD) relative to D614G.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	24	24	24						0	A=24	24	A	C	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	24	24	24						0	A=24	24	A	C	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 7.8% to 1.2% (significantly poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del,N501Y, A570D Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	24	24	24						0	A=24	24	A	C	antibody epitope effects	Johnson et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457603/ 		This variant is adjacent to the Spike protein furin cleavage site (cleavage of S into S1 and S2 subunits is required for viral membrane fusion and subsequent entry into host cells), a site shown to be highly immunogenic.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	24	24	24						0	A=24	24	A	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.26x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	24	24	24						0	A=24	24	A	C	trafficking	Lubinski et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.06.438731v1		While the introduction of P681H in the SARS-CoV-2 B.1.1.7 variant may increase spike cleavage by furin-like proteases,  this does not significantly impact viral entry or cell-cell spread. We consider that other factors are at play to account  for the increased in transmission and disease severity attributed to this variant of concern (VOC).	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	24	24	24						0	A=24	24	A	C	trafficking	Maaroufi (2021)	https://www.researchgate.net/publication/348943694_The_mutation_P681H_in_the_B117_variant_of_SARS-CoV-2_probably_enhances_viral_entry_and_replication		This mutation in the first base of the furin clevage site maintains the RXXR recognition motif, and is presumed to enhance cleavage based on the removal of a proline-directed phosphotase recognition site at S680. In a homologuous site in Infectious  Bronchitis Virus (IBV, Gammacoronaviruses), abolition of S680 phosphorylation improves furin cleavage  (and presumably cell entry).	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	24	24	24						0	A=24	24	A	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing NO statistically significant infection rate change amongst the cells, suggesting that furin cleavage typically used for cell entry is not affected by this change one  amino acid upstream of the RXXR recognition pattern. 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	24	24	24						0	A=24	24	A	C	vaccine neutralization efficacy	Zuckerman et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.25.21253908v1	'D614G'	No significant change in virus neutralzation by 18 Pfizer two dose vaccinee sera compared to B.1.1.7. [results without including the used mutation A27S likely generalizable, as this is not a lineage defining mutation]	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	24	24	24						0	A=24	24	A	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.14x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P681H	c.C2042A	p.P681H			23604	S	S	MISSENSE	24	24	24						0	A=24	24	A	C	virion structure	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The Ratio of S2 (processed Spike) to full length Spike is higher for this mutation,  due to a drop in the full length Spike measured, suggesting that this mutation compensates for decreased Spike production by improved proteolytic processing.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.P68P	c.T204A	p.P68P			27597	ORF7a	ORF7a	SILENT	23	24	24						19	A=4	4	A	T						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.RG203KR	c.GGG608_610AAC	p.RG203KR			28881	N	N		24	24	24						0	AAC=24	24	AAC	GGG						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.S3675del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'3676del', 'F3677del'	11287	orf1ab	ORF1ab		24	24	24			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=24	24	G	GTCTGGTTTT						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.S940S	c.C2820T	p.S940S			24382	S	S	SILENT	24	24	24						0	T=24	24	T	C						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.T1238T	c.C3714A	p.T1238T			25276	S	S	SILENT	24	24	24						0	A=24	24	A	C						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.T1542I	c.C4625T	p.T1542I			4890	orf1ab	ORF1ab	MISSENSE	24	24	24			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	21	T=3	3	T	C						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.T2936I	c.C8807T	p.T2936I			9072	orf1ab	ORF1ab	MISSENSE	24	24	24			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	T=24	24	T	C						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.T3284I	c.C9851T	p.T3284I			10116	orf1ab	ORF1ab	MISSENSE	24	24	24			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	T=24	24	T	C						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	24	24	24						0	T=24	24	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.33x decrease in binding (KD) relative to D614G.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	24	24	24						0	T=24	24	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	No change in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.T95I	c.C284T	p.T95I			21846	S	S	MISSENSE	24	24	24						0	T=24	24	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.02x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.V6772M	c.G20314A	p.V6772M			20578	orf1ab	ORF1ab	MISSENSE	24	24	24			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	A=24	24	A	G						False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.W128R	c.T382A	p.W128R			25774	ORF3a	ORF3a	MISSENSE	24	24	24						19	A=5	5	A	T						False	B.1.1.318	B.1.1.318=False	VUM			02-Jun-2021
p.Y144del	c.429_431delTTA	p.Y144del			21990	S	S		20	24	24						2	T=18	18	T	TTTA	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a slight decrease in binding (KD) relative to D614G.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.Y144del	c.429_431delTTA	p.Y144del			21990	S	S		20	24	24						2	T=18	18	T	TTTA	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 1% to 0.17% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: N501Y, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen. 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.Y144del	c.429_431delTTA	p.Y144del			21990	S	S		20	24	24						2	T=18	18	T	TTTA	antibody epitope effects	McCallum et al. (2021)	https://doi.org/10.1101/2021.01.14.426475		"Massive reduction in S2M28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X333 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition) "	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.Y144del	c.429_431delTTA	p.Y144del			21990	S	S		20	24	24						2	T=18	18	T	TTTA	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Abolishes neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.Y144del	c.429_431delTTA	p.Y144del			21990	S	S		20	24	24						2	T=18	18	T	TTTA	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.14x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.Y144del	c.429_431delTTA	p.Y144del			21990	S	S		20	24	24						2	T=18	18	T	TTTA	convalescent plasma escape	McCarthy et al. (2021)	https://doi.org/10.1126/science.abf6950		Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 4 patients.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.Y144del	c.429_431delTTA	p.Y144del			21990	S	S		20	24	24						2	T=18	18	T	TTTA	immunosuppression variant emergence	Avanzato et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7640888/		Emergent as 100% variant from larger minor (1% allele frequency) deletion by day 70 post-infection of female immunocompromised  individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia. Variant disappeared after convalescent plasma treatment (day 71) in subsequent sample sequencing.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.Y144del	c.429_431delTTA	p.Y144del			21990	S	S		20	24	24						2	T=18	18	T	TTTA	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells. 	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
p.Y144del	c.429_431delTTA	p.Y144del			21990	S	S		20	24	24						2	T=18	18	T	TTTA	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.08x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.1.318	B.1.1.318=True	VUM			02-Jun-2021
